Original Report

Evaluation of a policy of lymph node retrieval for colon cancer specimens: a quality improvement opportunity


 

Background In an effort to improve compliance with the national guidelines of adequate lymph node harvest for colon cancer, the Department of Pathology at the Valley Health System in Paramus, New Jersey, established a policy in 2011 stating that if fewer than 12 lymph nodes were evaluated after initial dissection of a non-metastatic invasive colon cancer specimen, then re-dissection of the specimen was performed to harvest additional lymph nodes.
Objective To evaluate the efficacy of the policy as it relates to the compliance for sufficient lymph node evaluation in non-metastatic invasive colon cancers.
Methods A review of the Valley Hospital Health System Tumor Registry for all adult patients who had undergone surgery for stages I-III colon adenocarcinoma during January 1, 2007-July 1, 2015 identified 626 patients. The patients were divided into 2 groups, pre-policy (n = 301) and post-policy (n = 325), for analysis.
Results The median lymph node yield in the post-policy group increased significantly and the percentage of inadequate lymph node evaluation significantly decreased, compared with the pre-policy group. With the improvement of lymph node yields, fewer patients received chemotherapy for stage II colon cancer. Overall survival of patients with adequate lymph node yields was significantly longer than in patients with inadequate yields.
Limitations Single institutional study with relatively small numbers.
Conclusions The results of this study suggest that the implementation of a policy of reflexive re-dissection for colon cancer specimens with inadequate lymph node yields decreases the number of insufficient lymph node specimens and significantly improves compliance with national guidelines.
To read the full article, click on the PDF icon at the top of this introduction.

Recommended Reading

Gene profile predicts RCC response to nivolumab
MDedge Hematology and Oncology
Salvage RT may reduce risk of prostate cancer metastasis even at low PSA levels
MDedge Hematology and Oncology
Active surveillance may be feasible for some advanced RCC patients
MDedge Hematology and Oncology
Prostate cancer incidence continues to decrease after recommendation against screening
MDedge Hematology and Oncology
Study supports extending docetaxel therapy in metastatic castration-resistant prostate cancer
MDedge Hematology and Oncology
Drug combo shows promise for non–clear cell renal cell carcinoma
MDedge Hematology and Oncology
New anticancer drugs linked to increased costs, life expectancy
MDedge Hematology and Oncology
FDA modifies dosage regimen for nivolumab
MDedge Hematology and Oncology
No link between vasectomy, prostate cancer in U.S. cohort
MDedge Hematology and Oncology
10-year follow-up: Localized prostate cancer treatments offer similar efficacy
MDedge Hematology and Oncology